Search Within

Department of Medicine

Formats
  1. Journal Article (19590)
  2. Meeting Abstract (16038)
  3. Review (1149)
  4. Book Section (934)
  5. Editorial (608)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22319)
  2. Hematologic Malignancies, Division of (13275)
  3. Center for Hematologic Malignancies (11059)
  4. GSK Faculty (10645)
  5. Survivorship Research (9329)
  6. Division of Subspecialty Medicine (7534)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1065)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2110)

More Publishers

Results (39616)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Superiority of post-transplant cyclophosphamide-based graft versus host disease (GvHD) prophylaxis in patients 70 years and older: A BMT CTN 1703 post-hoc analysis
    Meeting Abstract

    Abedin, S.; Lian, Q. H.; Martens, M. J.; Malki, M. M. A.; Elmariah, H.; Gooptu, M.; Larkin, K. T.; Shaffer, B. C.; Loren, A. W.; Solh, M. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Increased inflammatory cytokines in plasma are associated with sustained treatment-free remission in chronic myeloid leukaemia
    Meeting Abstract

    Kok, C. H.; Saunders, V. A.; Shanmuganathan, N.; Liu, L.; Irani, Y. D.; Clarson, J.; Dang, P.; Yeung, D. T.; Yong, A. S. M.; Branford, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Systematic evaluation of GAPs and GEFs identifies ARHGAP45 as a targetable leukemia-specific dependency
    Meeting Abstract

    Zhang, P.; Cao, Z.; Pan, X.; Liu, Y.; Castro, C.; Kim, W. J.; Fujino, T.; Lewis, J.; Rahman, J.; Shahid, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Obecabtagene autoleucel (obe-cel) for adult relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Deep molecular remission may predict better outcomes
    Meeting Abstract

    Jabbour, E.; Park, J. H.; Shaughnessy, P.; Logan, A. C.; Sandhu, K. S.; Abedi, M.; Shah, B. D.; Bishop, M. R.; DeAngelo, D. J.; Lao-Sirieix, P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Results from the first phase 1 clinical study of DR-01, a non-fucosylated anti-CD94 targeting antibody in patients with relapsed/refractory cytotoxic lymphomas: Dose escalation and optimization
    Meeting Abstract

    Zain, J.; Iyer, S. P.; Marchi, E.; Gandhi, M.; Kim, Y. H.; Khodadoust, M. S.; Brammer, J. E.; Poh, C.; Porcu, P.; Dilley, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CAR-tography: Longitudinal mapping of CAR-T toxicities across B-cell malignancies reveals biologically distinct and prognostically relevant toxicity phenotypes
    Meeting Abstract

    Rejeski, K.; Fei, T.; Luna, A.; Alhomoud, M.; Valtis, Y. K.; Nishimura, N.; Gomez-Llobell, M.; Accav, N. G.; Beyar-Katz, O.; Raj, S. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Burden of idiopathic multicentric Castleman disease (iMCD) in the US: A population-level real world analysis using a health-claims dataset
    Meeting Abstract

    Noy, A.; Ohgami, R.; Munshi, N. C.; Siddiqi, I.; Dacus, K. C.; Saltis, A. W.; Shupo, F.; Princic, N.; Evans, K.; Mukherjee, S.
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab with dose-adjusted EPOCH is feasible in newly diagnosed plasmablastic lymphoma: AIDS Malignancy Consortium 105
    Meeting Abstract

    Noy, A.; Barta, S. K.; Kwon, D.; Baiocchi, R.; Ramos, J. C.; Rubinstein, P.; Chadburn, A.; Ambinder, R. F.
    Blood (2024)

    Fulltext@MSK | Save
  • Fixed-duration glofitamab monotherapy continues to demonstrate durable responses in patients with relapsed or refractory large B-cell lymphoma: 3-year follow-up from a pivotal phase II study
    Meeting Abstract

    Dickinson, M. J.; Carlo-Stella, C.; Morschhauser, F.; Bachy, E.; Cartron, G.; Corradini, P.; Bartlett, N. L.; Iacoboni, G.; Khan, C.; Hertzberg, M. S.; more...
    Blood (2024)

    Fulltext@MSK | Save